The ARTEMIS-002 study is a multi-center, open-label Phase II clinical study (NCT05830123) designed to evaluate the effectiveness, safety and efficacy of intravenous administration of HS-20093 in patients with relapsed or refractory bone and soft tissue sarcoma.

Kinetic characteristics and immunogenicity.

The study is divided into Phase IIa and Phase IIb. Phase IIa evaluates the effectiveness, safety, PK characteristics and immunogenicity of different doses of HS-20093 in the target population in subjects with relapsed or refractory bone and soft tissue sarcoma. The Phase IIb clinical study will evaluate the effectiveness, safety, PK characteristics and immunogenicity of HS-20093 in subjects with relapsed or refractory osteosarcoma.

HS-20093 is an antibody conjugate drug targeting B7-H3 independently developed by Hansoh Pharmaceuticals. Based on the phase Ia dose escalation study data (ARTEMIS-001, NCT05276609) published at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, it has been Positive efficacy signals were observed in sarcoma patients , and the further AR TEMIS-002 study has received widespread attention from sarcoma experts at home and abroad.

At present, Hansoh Pharmaceutical has initiated and accelerated the research on HS-20093 for bone and soft tissue sarcoma in China. At the same time, it will also work with the authorized transaction party GlaxoSmithKline (GSK) to continue to promote the overseas research progress of HS-20093, with a view to providing China with It even brings good news to osteosarcoma patients around the world.

About the International Connective Tissue Tumor Society

Founded in 1997, the International Connective Tissue Tumor Society (CTOS) is an international organization composed of physicians and scientists concerned with connective tissue tumors. The CTOS Annual Meeting held every year is the largest, most comprehensive, most fruitful, and most innovative academic event in the field of connective tissue tumors in the world, covering related diseases such as osteosarcoma, soft tissue sarcoma, and gastrointestinal stromal tumors.

About Hansoh Pharmaceuticals

Hansoh Pharmaceuticals is China's leading innovation-driven pharmaceutical company. It has subsidiaries such as Hansoh Pharmaceuticals, Changzhou Hengbang Pharmaceuticals, and Hansoh Biopharmaceuticals, focusing on anti-tumor, anti-infection, central nervous system, metabolism, and autoimmunity. In the field of treatment of major diseases, we are committed to improving the quality of human life through continuous innovation. So far, the company has launched 7 innovative drugs, and the revenue share of innovative drugs has exceeded 61.8%. The company has been ranked among the top 100 global pharmaceutical companies and among the top 3 industrial companies with the best pharmaceutical R&D product lines in China for many consecutive years. It is a national key high-tech enterprise and a national technological innovation demonstration enterprise. The company was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).

Contact:

Tel: 0518-83096666

Email: PV.SERVICE@hspharm.com

(C) 2024 Electronic News Publishing, source ENP Newswire